Kontakt

Dr. Michael Mende
Dr. Michael Mende
Program Coordinator IMPRS-TP | EKF-TP
Telefon: +49 (0) 89-30622-273
Oktober 2018
Mo Di Mi Do Fr Sa So
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Programm MPLS

Max-Planck-Gesundheitsforum

Weitere Seminare

Weitere Ankündigungen zu Seminaren und Veranstaltungen im Raum München finden sich unter folgenden Verlinkungen:

Munich Neuroscience Lecture Series

Munich Neuroscience Calendar

Life Science Campus Seminars

Fort- und Weiterbildung

Seminare

15477 1537778658

Characterization of novel mouse model reveals a new role for FKBP5

Single nucleotide polymorphisms (SNPs) in FK506-binding protein 5 (FKBP5) have been shown to combine with environmental factors increases risk for psychiatric diseases, like post-traumatic stress disorder (PTSD). While mechanisms of FKBP5 contribution to this increased risk are still under investigation, it has been shown that many of these SNPs increase FKBP5 expression through decreased FKBP5 DNA methylation. To evaluate the consequences of this enhanced expression, we generated a novel mouse model using targeted insertion of a single copy of the FKBP5 gene at the Hipp11 locus. The inserted FKBP5 contained a tetracycline operator, which allowed for high expression throughout the forebrain when crossed with an activator line. Evaluation of this model was done using behavioral, electrophysiological, and biochemical analysis. Overall, we have found that high expression of FKBP5 alters memory as tested by both Morris water maze and long-term depression. Importantly, this alteration was detectable in the absence of stress and other environmental factors. Further studies in this model may help reveal additional mechanisms by which FKBP5 alters learning and memory. [mehr]

Munich Psychiatry Lecture Series | MPLS

14880 1533549303

Personalized medicine in Depression: hype or hope?

Symptom profiles, etiology and course trajectories of Major Depressive Disorder (MDD) are heterogeneous. This heterogeneity is hampering scientific research and is limiting effectiveness of therapeutic interventions. The goal of precision medicine is to tailor medical treatment to the individual characteristics of each patient. In order to implement precision medicine in depression care, it is essential to better understand what the driving factors are behind MDD’s heterogeneity. However, examining MDD’s heterogeneity is no sinecure, and there are various different ways to start such scientific explorations. One could start with data-driven or hypothesis-driven approaches, one could start with a focus on the heterogeneity at the symptom level, the environment level or the pathophysiology level. Ideally, whatever the starting point is should not matter and results of different starting points should synchronize. Using several different analytical approaches, our research group has illustrated the distinction of immunometabolic depression as a potentially useful subtype of depression. [mehr]

 
Zur Redakteursansicht
loading content